Zepbound (Tirzepatide)
$260.00Zepbound (tirzepatide) is an FDA-approved dual GIP/GLP-1 receptor agonist specifically indicated for chronic weight management in adults with obesity or overweight conditions with weight-related comorbidities.
Available: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg
In Stock (110 available)
Why Choose Zepbound?
Engineered by Eli Lilly specifically with weight-loss protocols in mind, activating both GIP and GLP-1 pathways for maximum reduction of adipose tissue.
How to Use
Inject subcutaneously once weekly into the abdomen, thigh, or upper arm on the same day every week with or without food.
Safety Information
Contraindicated in patients with a history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
Potential Side Effects
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, and fatigue.
Product Facts
| Generic Name | Tirzepatide |
| Brand Name | Zepbound |
| Type of Medication | Dual GIP and GLP-1 Receptor Agonist |
| FDA Approval Date | November 8, 2023 |
| Indications | Specifically FDA-approved for chronic weight management in adults with obesity (BMI >= 30) or overweight (BMI >= 27) with at least one weight-related condition. |
| Dosage Forms | Single-dose prefilled autoinjector pen (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg per 0.5 mL) |
| Administration | Once weekly subcutaneous injection (Every 7 days) |
| Special Precautions | Boxed warning for thyroid C-cell tumors. Not recommended in patients with severe gastrointestinal disease or history of pancreatitis. |
| Drug Interactions | Delays gastric emptying; may impact absorption of concomitant oral drugs including oral birth control. |
| Use in Specific Populations | Contraindicated during pregnancy. Discontinue when pregnancy is recognized. |
| Prescription | Prescription Required |
| Manufacturer | Eli Lilly and Company |
How to Buy
Choose your titration strength, add to cart, and receive discreet refrigerated delivery.